Gossamer Bio, Inc.
gossamerbio.comWhat Do They Do?
Develops seralutinib, an investigational medicine for people with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
10-K for FY2025, filed Mar 17, 2026
How Do They Make Money?
Chiesi pays a one-time development-cost reimbursement for licenses and ongoing cost-sharing payments for research and development services as Gossamer performs them; separate license fees arrive when the licensee can use the license.
10-K for FY2025, filed Mar 17, 2026To date, we have generated all of our revenue from the Chiesi Collaboration Agreement. Our revenue consists of a one-time development cost…View ↗
For arrangements that include cost-share reimbursements, we will recognize such payments when control of the related goods or services are…View ↗
If a license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in a…View ↗
-
10-K for FY2025, filed Mar 17, 2026
FY2025 revenue by product or service ↗
$48.5M
-
10-K for FY2025, filed Mar 17, 2026
$48.5M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Revenue from sale of licenses
Licensed
|
0.0% |
Revenue from sale of licenses, FY2025
$0 Sources
|
Licensed |
|
Revenue from contracts with collaborators
|
100% |
Revenue from contracts with collaborators, FY2025
$48.5M Sources
|
Who Are Their Customers?
Gossamer's seralutinib collaborator was Chiesi: they shared development and U.S. commercialization work, while Chiesi held exclusive rights to commercialize outside the U.S.
10-K for FY2025, filed Mar 17, 2026In May 2024, we entered into a collaboration agreement with Chiesi. Under the collaboration agreement, we will jointly develop seralutinib…View ↗
Do Revenues Turn Into Profits?
No. It lost $170.4M in FY2025.
10-K for FY2025, filed Mar 17, 2026
−$170.7MView ↗
10-K for FY2025, filed Mar 17, 2026
−$170.4MView ↗
10-K for FY2025, filed Mar 17, 2026
−$171.3MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
$16.9MView ↗
- ▲ Now profitable
- vs −$38.3M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 13, 2026
Open tableView ↗
-
Jul 27, 2026
Gossamer reacquired worldwide seralutinib development and commercial rights from Chiesi
The parties terminated their collaboration agreement and transferred related seralutinib assets to Gossamer.
Sources
8-K, filed Jul 27, 2026
On July 23, 2026, Gossamer Bio, Inc. (the “Company” or “Gossamer”), Gossamer Bio USA, Inc. (formerly GB002, Inc.) and Gossamer Bio 002…View ↗
A narrower drug focus
The earlier business description covered immunology, inflammation and oncology, including drug candidates for lymphoma and multiple sclerosis and preclinical programs; the current description focuses on seralutinib for pulmonary hypertension.
10-K for FY2022, filed Mar 17, 2023 10-K for FY2025, filed Mar 17, 2026We are a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the…View ↗
GB5121 (CNS-Penetrant BTK Inhibitor)View ↗
GB7208 is an oral, small molecule, BTK inhibitor in preclinical development for the treatment of multiple sclerosis, or MS. Like GB5121…View ↗
Including GB7208, we have multiple programs in preclinical development, with a focus on the therapeutic areas of immunology, inflammation…View ↗
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of…View ↗
Who Do They Compete With?
Competes with United Therapeutics, Janssen, Liquidia, Merck, Pfizer, Bayer, Gilead Sciences, Cereno Scientific, Insmed, Regeneron, Novartis, Apollo Therapeutics, AllRock Bio, OrphAI Therapeutics, Pulmovant, and ForeSee Pharmaceuticals
10-K for FY2025, filed Mar 17, 2026We expect to face competition for seralutinib and RT234 from existing products and products in development. Seralutinib is a PDGFR, CSF1R…View ↗
Loading...
